Combined HAT/EZH2 modulation leads to cancer-selective cell death

Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce cancer-selective cell death in both solid and hematological cancers , and xenograft mode...

Full description

Saved in:
Bibliographic Details
Published inOncotarget Vol. 9; no. 39; pp. 25630 - 25646
Main Authors Petraglia, Francesca, Singh, Abhishek A., Carafa, Vincenzo, Nebbioso, Angela, Conte, Mariarosaria, Scisciola, Lucia, Valente, Sergio, Baldi, Alfonso, Mandoli, Amit, Petrizzi, Valeria Belsito, Ingenito, Concetta, De Falco, Sandro, Cicatiello, Valeria, Apicella, Ivana, Janssen-Megens, Eva M., Kim, Bowon, Yi, Guoqiang, Logie, Colin, Heath, Simon, Ruvo, Menotti, Wierenga, Albertus T.J., Flicek, Paul, Yaspo, Marie Laure, Della Valle, Veronique, Bernard, Olivier, Tomassi, Stefano, Novellino, Ettore, Feoli, Alessandra, Sbardella, Gianluca, Gut, Ivo, Vellenga, Edo, Stunnenberg, Hendrik G., Mai, Antonello, Martens, Joost H.A., Altucci, Lucia
Format Journal Article
LanguageEnglish
Published United States Impact journals 22.05.2018
Impact Journals LLC
Subjects
Cancer
Life Sciences
Research Paper
acetylation
apoptosis
cancer
methylation
epigenetics
Online AccessGet full text
ISSN1949-2553
1949-2553
DOI10.18632/oncotarget.25428

Cover

Abstract Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce cancer-selective cell death in both solid and hematological cancers , and xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53 or TET2 cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in human primary leukemia blasts with poor prognosis , by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors. Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to 'personalize' precision medicine.
AbstractList Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce bona fide cancer-selective cell death in both solid and hematological cancers in vitro , ex vivo and in vivo xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53 –/– or TET2 –/– cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in ex vivo human primary leukemia blasts with poor prognosis in vivo , by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors. Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to ‘personalize’ precision medicine.
Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce bona fide cancer-selective cell death in both solid and hematological cancers in vitro, ex vivo and in vivo xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53-/- or TET2-/- cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in ex vivo human primary leukemia blasts with poor prognosis in vivo, by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors. Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to 'personalize' precision medicine.
Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce bona fide cancer-selective cell death in both solid and hematological cancers in vitro, ex vivo and in vivo xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53-/- or TET2-/- cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in ex vivo human primary leukemia blasts with poor prognosis in vivo, by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors. Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to 'personalize' precision medicine.Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce bona fide cancer-selective cell death in both solid and hematological cancers in vitro, ex vivo and in vivo xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53-/- or TET2-/- cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in ex vivo human primary leukemia blasts with poor prognosis in vivo, by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors. Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to 'personalize' precision medicine.
Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce cancer-selective cell death in both solid and hematological cancers , and xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53 or TET2 cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in human primary leukemia blasts with poor prognosis , by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors. Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to 'personalize' precision medicine.
Author Carafa, Vincenzo
Altucci, Lucia
Cicatiello, Valeria
Nebbioso, Angela
Petrizzi, Valeria Belsito
Scisciola, Lucia
De Falco, Sandro
Yaspo, Marie Laure
Feoli, Alessandra
Mandoli, Amit
Valente, Sergio
Mai, Antonello
Yi, Guoqiang
Singh, Abhishek A.
Janssen-Megens, Eva M.
Baldi, Alfonso
Wierenga, Albertus T.J.
Tomassi, Stefano
Ruvo, Menotti
Conte, Mariarosaria
Apicella, Ivana
Gut, Ivo
Stunnenberg, Hendrik G.
Petraglia, Francesca
Flicek, Paul
Della Valle, Veronique
Bernard, Olivier
Ingenito, Concetta
Martens, Joost H.A.
Heath, Simon
Novellino, Ettore
Vellenga, Edo
Logie, Colin
Sbardella, Gianluca
Kim, Bowon
Author_xml – sequence: 1
  givenname: Francesca
  surname: Petraglia
  fullname: Petraglia, Francesca
  organization: Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
– sequence: 2
  givenname: Abhishek A.
  surname: Singh
  fullname: Singh, Abhishek A.
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands
– sequence: 3
  givenname: Vincenzo
  surname: Carafa
  fullname: Carafa, Vincenzo
  organization: Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
– sequence: 4
  givenname: Angela
  surname: Nebbioso
  fullname: Nebbioso, Angela
  organization: Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
– sequence: 5
  givenname: Mariarosaria
  surname: Conte
  fullname: Conte, Mariarosaria
  organization: IRCCS SDN, Napoli 80143, Italy
– sequence: 6
  givenname: Lucia
  surname: Scisciola
  fullname: Scisciola, Lucia
  organization: Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
– sequence: 7
  givenname: Sergio
  surname: Valente
  fullname: Valente, Sergio
  organization: Dipartimento di Chimica e Tecnologie del Farmaco ‘Sapienza’ Università, Roma 00185, Italy
– sequence: 8
  givenname: Alfonso
  surname: Baldi
  fullname: Baldi, Alfonso
  organization: Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, Università della Campania ‘Luigi Vanvitelli’, Caserta 81100, Italy
– sequence: 9
  givenname: Amit
  surname: Mandoli
  fullname: Mandoli, Amit
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands
– sequence: 10
  givenname: Valeria Belsito
  surname: Petrizzi
  fullname: Petrizzi, Valeria Belsito
  organization: Ospedale Umberto I, Nocera Inferiore 84014, Italy
– sequence: 11
  givenname: Concetta
  surname: Ingenito
  fullname: Ingenito, Concetta
  organization: Ospedale Umberto I, Nocera Inferiore 84014, Italy
– sequence: 12
  givenname: Sandro
  surname: De Falco
  fullname: De Falco, Sandro
  organization: Istituto di Genetica e Biofisica, Napoli 80131, Italy
– sequence: 13
  givenname: Valeria
  surname: Cicatiello
  fullname: Cicatiello, Valeria
  organization: Istituto di Genetica e Biofisica, Napoli 80131, Italy
– sequence: 14
  givenname: Ivana
  surname: Apicella
  fullname: Apicella, Ivana
  organization: Istituto di Genetica e Biofisica, Napoli 80131, Italy
– sequence: 15
  givenname: Eva M.
  surname: Janssen-Megens
  fullname: Janssen-Megens, Eva M.
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands
– sequence: 16
  givenname: Bowon
  surname: Kim
  fullname: Kim, Bowon
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands
– sequence: 17
  givenname: Guoqiang
  surname: Yi
  fullname: Yi, Guoqiang
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands
– sequence: 18
  givenname: Colin
  surname: Logie
  fullname: Logie, Colin
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands
– sequence: 19
  givenname: Simon
  surname: Heath
  fullname: Heath, Simon
  organization: Centro Nacional de Análisis Genómico, Barcelona, Spain
– sequence: 20
  givenname: Menotti
  surname: Ruvo
  fullname: Ruvo, Menotti
  organization: Istituto di Biostrutture e Bioimmagini, Napoli, Italy
– sequence: 21
  givenname: Albertus T.J.
  surname: Wierenga
  fullname: Wierenga, Albertus T.J.
  organization: Department of Hematology, University of Groningen and University Medical Center Groningen, RB Groningen 9700, The Netherlands
– sequence: 22
  givenname: Paul
  surname: Flicek
  fullname: Flicek, Paul
  organization: European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom
– sequence: 23
  givenname: Marie Laure
  surname: Yaspo
  fullname: Yaspo, Marie Laure
  organization: Max Planck Institute for Molecular Genetics, Berlin, Germany
– sequence: 24
  givenname: Veronique
  surname: Della Valle
  fullname: Della Valle, Veronique
  organization: Institute Gustave Roussy, Equipe labellisée Ligue Nationale contre le Cancer (LNCC), Universtité Paris-Saclay, INSERM U1170, Paris, France
– sequence: 25
  givenname: Olivier
  surname: Bernard
  fullname: Bernard, Olivier
  organization: Institute Gustave Roussy, Equipe labellisée Ligue Nationale contre le Cancer (LNCC), Universtité Paris-Saclay, INSERM U1170, Paris, France
– sequence: 26
  givenname: Stefano
  surname: Tomassi
  fullname: Tomassi, Stefano
  organization: Dipartimento di Farmacia, Università di Napoli ‘Federico II’, Napoli 80131, Italy
– sequence: 27
  givenname: Ettore
  surname: Novellino
  fullname: Novellino, Ettore
  organization: Dipartimento di Farmacia, Università di Napoli ‘Federico II’, Napoli 80131, Italy
– sequence: 28
  givenname: Alessandra
  surname: Feoli
  fullname: Feoli, Alessandra
  organization: Dipartimento di Farmacia, Università degli Studi di Salerno, Fisciano I-84084, Italy
– sequence: 29
  givenname: Gianluca
  surname: Sbardella
  fullname: Sbardella, Gianluca
  organization: Dipartimento di Farmacia, Università degli Studi di Salerno, Fisciano I-84084, Italy
– sequence: 30
  givenname: Ivo
  surname: Gut
  fullname: Gut, Ivo
  organization: Centro Nacional de Análisis Genómico, Barcelona, Spain
– sequence: 31
  givenname: Edo
  surname: Vellenga
  fullname: Vellenga, Edo
  organization: Department of Hematology, University of Groningen and University Medical Center Groningen, RB Groningen 9700, The Netherlands
– sequence: 32
  givenname: Hendrik G.
  surname: Stunnenberg
  fullname: Stunnenberg, Hendrik G.
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands
– sequence: 33
  givenname: Antonello
  surname: Mai
  fullname: Mai, Antonello
  organization: Dipartimento di Chimica e Tecnologie del Farmaco ‘Sapienza’ Università, Roma 00185, Italy, Pasteur Institute, Cenci-Bolognetti Foundation, Sapienza University of Rome, Roma 00185, Italy
– sequence: 34
  givenname: Joost H.A.
  surname: Martens
  fullname: Martens, Joost H.A.
  organization: Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
– sequence: 35
  givenname: Lucia
  surname: Altucci
  fullname: Altucci, Lucia
  organization: Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29876013$$D View this record in MEDLINE/PubMed
https://hal.science/hal-01873834$$DView record in HAL
BookMark eNp1kUtv1DAUhS1UREvbH8AGZUkXaf2IH9kgjUYtgzQSm7LpxrqxbzpGiV1iz0j8e9KZFkolvLHle87n63vek6OYIhLygdFLZpTgVym6VGC6x3LJZcPNG3LC2qatuZTi6MX5mJzn_IPOSzba8PYdOeat0YoycUIWyzR2IaKvVovbq-u7Fa_G5LcDlJBiNSD4XJVUOYgOpzrjgK6EHVYOh6HyCGVzRt72MGQ8f9pPyfeb69vlql5_-_J1uVjXTjTG1L3y6AV63XGtjJQaPAhPlQcQEhsqDe3RS-jpXGyd7pjooBW96DpwnPfilHw-cB-23YjeYSwTDPZhCiNMv2yCYP-txLCx92lnZWuUks0MuDgANq9sq8XaPt5RZrQwotmxWfvp6bEp_dxiLnYM-fHPEDFts-VUMqW4kHqWfnzZ1x_y84xngT4I3JRynrC3LpT9fOc2w2AZtftA7d9A7T7Q2cleOZ_h__f8BuQqpt4
CitedBy_id crossref_primary_10_1016_j_semcancer_2020_12_004
crossref_primary_10_3390_molecules25143122
crossref_primary_10_1016_j_celrep_2018_12_098
Cites_doi 10.1038/sj.onc.1210608
10.1016/j.febslet.2010.04.002
10.1182/blood-2008-01-136366
10.1016/j.celrep.2016.08.082
10.1182/blood.V88.7.2671.bloodjournal8872671
10.1021/acs.jmedchem.5b01117
10.1038/leu.2011.271
10.1056/NEJMoa1301689
10.1158/1078-0432.CCR-15-0530
10.1016/j.celrep.2015.07.024
10.1182/blood-2011-10-386086
10.1016/j.molonc.2012.09.004
10.1038/nrc3130
10.1002/jcb.24000
10.1056/NEJMoa1516192
10.1021/jm4012802
10.1158/0008-5472.CAN-13-2568
10.1056/NEJMoa0810069
10.1016/j.bbadis.2010.10.005
10.1038/nrd4360
10.1186/1471-2407-10-524
10.1158/1078-0432.CCR-12-2037
10.1124/mi.9.6.7
10.1016/j.ccr.2011.06.003
10.1016/j.ccr.2012.06.008
10.1038/nature09504
10.1177/1947601911418499
10.1038/ng.2764
10.1038/nm1161
10.1038/embor.2009.88
10.1089/ars.2013.5776
10.1186/gb-2005-6-8-227
10.1038/nrg3173
10.3892/ijo.2014.2766
10.1038/leu.2017.64
10.1158/1535-7163.MCT-15-0429
10.1038/416552a
10.1158/0008-5472.CAN-13-3056
10.1517/14728222.2015.1051728
10.1016/j.ccell.2016.09.014
10.1016/j.biochi.2012.06.003
10.1186/s13148-016-0223-4
10.1371/journal.pone.0083737
10.18632/oncotarget.2816
10.1158/1078-0432.CCR-15-2388
10.1089/scd.2012.0498
10.1016/j.biocel.2015.10.016
10.1002/pmic.201500223
10.1080/15592294.2016.1249089
10.1371/journal.pone.0084147
10.1016/j.cell.2013.03.008
10.1038/cddis.2012.109
10.3389/fonc.2015.00108
10.1017/S1462399411001992
ContentType Journal Article
Copyright Attribution
Copyright: © 2018 Petraglia et al. 2018
Copyright_xml – notice: Attribution
– notice: Copyright: © 2018 Petraglia et al. 2018
DBID AAYXX
CITATION
NPM
7X8
1XC
VOOES
5PM
DOI 10.18632/oncotarget.25428
DatabaseName CrossRef
PubMed
MEDLINE - Academic
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1949-2553
EndPage 25646
ExternalDocumentID PMC5986654
oai_HAL_hal_01873834v1
29876013
10_18632_oncotarget_25428
Genre Journal Article
GroupedDBID ---
53G
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
FRJ
GX1
HYE
KQ8
M48
OK1
PGMZT
RPM
M~E
NPM
7X8
1XC
VOOES
5PM
ID FETCH-LOGICAL-c3488-f6ded3ed7b2768557ada3d06daa35e40580fed5af08559c7b13ba93f3bbac22f3
IEDL.DBID M48
ISSN 1949-2553
IngestDate Thu Aug 21 14:08:27 EDT 2025
Fri Sep 12 12:34:48 EDT 2025
Fri Jul 11 07:16:41 EDT 2025
Wed Feb 19 02:42:15 EST 2025
Tue Jul 01 02:03:16 EDT 2025
Thu Apr 24 23:00:12 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 39
Keywords acetylation
apoptosis
cancer
methylation
epigenetics
Language English
License Attribution: http://creativecommons.org/licenses/by
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3488-f6ded3ed7b2768557ada3d06daa35e40580fed5af08559c7b13ba93f3bbac22f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC5986654
These authors contributed equally to this work
ORCID 0000-0002-2181-2142
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.18632/oncotarget.25428
PMID 29876013
PQID 2051662357
PQPubID 23479
PageCount 17
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5986654
hal_primary_oai_HAL_hal_01873834v1
proquest_miscellaneous_2051662357
pubmed_primary_29876013
crossref_citationtrail_10_18632_oncotarget_25428
crossref_primary_10_18632_oncotarget_25428
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-05-22
2018-May-22
20180522
PublicationDateYYYYMMDD 2018-05-22
PublicationDate_xml – month: 05
  year: 2018
  text: 2018-05-22
  day: 22
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncotarget
PublicationTitleAlternate Oncotarget
PublicationYear 2018
Publisher Impact journals
Impact Journals LLC
Publisher_xml – name: Impact journals
– name: Impact Journals LLC
References Altucci (30) 2015; 69
Mandoli (47) 2014; 74
Schapira (24) 2013; 8
Johnstone (6) 2014; 13
McKeown (9) 2010; 468
Vogelstein (51) 2002; 416
Gronemeyer (44) 2005; 11
Vainchenker (42) 2008; 112
Richardson (23) 2015; 21
Shi (5) 2012; 13
Lania (21) 2016
Altucci (28) 2016
Altucci (20) 2012; 6
1
Jung (29) 2016; 8
Miller (37) 1996; 88
Jones (22) 2011; 11
Martincorena (17) 2016; 374
Tumber (35) 2014; 57
Collette (49) 2012; 26
Galinsky (50) 2015; 14
Brodeur (10) 2014; 74
Cencioni (46) 2016
Cheng (27) 2005; 6
Signorile (32) 2012; 113
Altucci (13) 2012; 18
Matarese (16) 2016; 17
Clarke (7) 2011; 2
Sarkar (11) 2015; 46
Cote (4) 2007; 26
Laird (15) 2013; 153
Jones (14) 2012; 22
Altucci (48) 2015; 6
Hohenfellner (25) 2010; 10
Tilly (41) 2011; 20
Altucci (33) 2013; 22
Mai (31) 2012; 94
Wang (3) 2015; 5
Knapp (8) 2011; 13
Carissimo (39) 2017
Altucci (45) 2009; 10
Stunnenberg (53) 2012; 120
Altucci (19) 2015; 19
Verdaguer-Dot (18) 2016; 30
Chambery (34) 2015
Altucci (38) 2015; 23
Stunnenberg (52) 2011; 1812
Borst (43) 2012; 3
Kutateladze (12) 2009; 9
Stunnenberg (54) 2010; 584
Dreyfus (40) 2009; 360
Stuart (2) 2013; 45
Gately Luz (26) 2013; 8
Stamatoyannopoulos (36) 2015; 12
21933453 - Expert Rev Mol Med. 2011 Sep 13;13:e29
27846393 - Cancer Cell. 2016 Nov 14;30(5):806-821
25131830 - Nat Rev Drug Discov. 2014 Sep;13(9):673-91
27276561 - N Engl J Med. 2016 Jun 9;374(23 ):2209-2221
22109698 - J Cell Biochem. 2012 Apr;113(4):1292-301
26206331 - Mol Cancer Ther. 2015 Oct;14 (10 ):2249-59
22923494 - Blood. 2012 Oct 11;120(15):3058-68
15619633 - Nat Med. 2005 Jan;11(1):77-84
24071849 - Nat Genet. 2013 Oct;45(10):1113-20
21941284 - Nat Rev Cancer. 2011 Sep 23;11(10):726-34
22789535 - Cancer Cell. 2012 Jul 10;22(1):9-20
19474426 - N Engl J Med. 2009 May 28;360(22):2289-301
24419087 - Cancer Res. 2014 Feb 1;74(3):652-8
20048137 - Mol Interv. 2009 Dec;9(6):314-23
26689352 - J Med Chem. 2016 Feb 25;59(4):1471-91
22904103 - Clin Cancer Res. 2012 Oct 15;18(20):5526-34
24382114 - Antioxid Redox Signal. 2015 Jul 1;23(1):99-126
23597129 - Stem Cells Dev. 2013 Sep 1;22(17 ):2368-83
21723201 - Cancer Cell. 2011 Jul 12;20(1):25-38
16086857 - Genome Biol. 2005;6(8):227
18755984 - Blood. 2008 Nov 15;112(10):4220-6
21979880 - Leukemia. 2012 Apr;26(4):662-74
17694081 - Oncogene. 2007 Aug 13;26(37):5395-407
27851970 - Cell Rep. 2016 Nov 15;17 (8):2087-2100
26494003 - Int J Biochem Cell Biol. 2015 Dec;69:121-31
23540689 - Cell. 2013 Mar 28;153(1):38-55
11932749 - Nature. 2002 Apr 4;416(6880):552-6
23103179 - Mol Oncol. 2012 Dec;6(6):657-82
27767379 - Epigenetics. 2017 Mar 4;12 (3):198-205
23634996 - N Engl J Med. 2013 May 30;368(22):2059-74
27222667 - Clin Epigenetics. 2016 May 24;8:57
24566867 - Cancer Res. 2014 Apr 15;74(8):2328-39
22875003 - Cell Death Dis. 2012 Aug 09;3:e366
20388510 - FEBS Lett. 2010 Jun 18;584(12):2662-9
25405367 - Int J Oncol. 2015 Feb;46(2):465-73
20871596 - Nature. 2010 Dec 23;468(7327):1067-73
26257180 - Cell Rep. 2015 Aug 18;12(7):1184-95
22473383 - Nat Rev Genet. 2012 Apr 03;13(5):343-57
8839862 - Blood. 1996 Oct 1;88(7):2671-82
26028314 - Expert Opin Ther Targets. 2015;19(9):1187-202
20970499 - Biochim Biophys Acta. 2011 Aug;1812(8):818-23
27358484 - Clin Cancer Res. 2017 May 15;23 (10 ):2542-2555
22709867 - Biochimie. 2012 Nov;94(11):2308-13
19498465 - EMBO Rep. 2009 Jul;10(7):776-82
25473896 - Oncotarget. 2015 Jan 20;6(2):886-901
24367637 - PLoS One. 2013 Dec 19;8(12 ):e84147
21941618 - Genes Cancer. 2011 Jun;2(6):618-30
24325601 - J Med Chem. 2014 Jan 9;57(1):42-55
28216661 - Leukemia. 2017 Nov;31(11):2315-2325
26604074 - Proteomics. 2016 Feb;16(4):674-88
20920340 - BMC Cancer. 2010 Oct 04;10:524
24367611 - PLoS One. 2013 Dec 19;8(12 ):e83737
26362997 - Clin Cancer Res. 2015 Nov 1;21(21):4767-73
26075180 - Front Oncol. 2015 May 26;5:108
References_xml – volume: 26
  start-page: 5395
  year: 2007
  ident: 4
  article-title: The MYST family of histone acetyltransferases and their intimate links to cancer
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210608
– volume: 584
  start-page: 2662
  year: 2010
  ident: 54
  article-title: The molecular signature of oncofusion proteins in acute myeloid leukemia
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2010.04.002
– volume: 112
  start-page: 4220
  year: 2008
  ident: 42
  article-title: Activating mutations in human acute megakaryoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2008-01-136366
– volume: 17
  start-page: 2087
  year: 2016
  ident: 16
  article-title: The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.08.082
– volume: 88
  start-page: 2671
  year: 1996
  ident: 37
  article-title: Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines
  publication-title: Blood
  doi: 10.1182/blood.V88.7.2671.bloodjournal8872671
– year: 2016
  ident: 46
  article-title: 1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.5b01117
– volume: 26
  start-page: 662
  year: 2012
  ident: 49
  article-title: Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1
  publication-title: Leukemia
  doi: 10.1038/leu.2011.271
– ident: 1
  doi: 10.1056/NEJMoa1301689
– volume: 21
  start-page: 4767
  year: 2015
  ident: 23
  article-title: Panobinostat for the Treatment of Multiple Myeloma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-0530
– volume: 12
  start-page: 1184
  year: 2015
  ident: 36
  article-title: Role of DNA Methylation in Modulating Transcription Factor Occupancy
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2015.07.024
– volume: 120
  start-page: 3058
  year: 2012
  ident: 53
  article-title: Chromatin accessibility, p300, and histone acetylation define PML-RARalpha and AML1-ETO binding sites in acute myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood-2011-10-386086
– volume: 6
  start-page: 657
  year: 2012
  ident: 20
  article-title: Trials with ‘epigenetic’ drugs: an update
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2012.09.004
– volume: 11
  start-page: 726
  year: 2011
  ident: 22
  article-title: A decade of exploring the cancer epigenome - biological and translational implications
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3130
– volume: 113
  start-page: 1292
  year: 2012
  ident: 32
  article-title: model of stromal and epithelial immortalized endometriotic cells
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.24000
– volume: 374
  start-page: 2209
  year: 2016
  ident: 17
  article-title: Genomic Classification and Prognosis in Acute Myeloid Leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1516192
– volume: 57
  start-page: 42
  year: 2014
  ident: 35
  article-title: Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities
  publication-title: J Med Chem
  doi: 10.1021/jm4012802
– volume: 74
  start-page: 2328
  year: 2014
  ident: 47
  article-title: Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-2568
– volume: 360
  start-page: 2289
  year: 2009
  ident: 40
  article-title: Mutation in TET2 in myeloid cancers
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0810069
– volume: 1812
  start-page: 818
  year: 2011
  ident: 52
  article-title: Genome-wide interplay of nuclear receptors with the epigenome
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbadis.2010.10.005
– volume: 13
  start-page: 673
  year: 2014
  ident: 6
  article-title: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4360
– volume: 10
  start-page: 524
  year: 2010
  ident: 25
  article-title: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-10-524
– volume: 18
  start-page: 5526
  year: 2012
  ident: 13
  article-title: Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-2037
– volume: 9
  start-page: 314
  year: 2009
  ident: 12
  article-title: PHD fingers: epigenetic effectors and potential drug targets
  publication-title: Mol Interv
  doi: 10.1124/mi.9.6.7
– volume: 20
  start-page: 25
  year: 2011
  ident: 41
  article-title: TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.06.003
– volume: 22
  start-page: 9
  year: 2012
  ident: 14
  article-title: Cancer genetics and epigenetics: two sides of the same coin?
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.06.008
– volume: 468
  start-page: 1067
  year: 2010
  ident: 9
  article-title: Selective inhibition of BET bromodomains
  publication-title: Nature
  doi: 10.1038/nature09504
– volume: 2
  start-page: 618
  year: 2011
  ident: 7
  article-title: The Roles of the Methyl-CpG Binding Proteins in Cancer
  publication-title: Genes Cancer
  doi: 10.1177/1947601911418499
– volume: 45
  start-page: 1113
  year: 2013
  ident: 2
  article-title: The Cancer Genome Atlas Pan-Cancer analysis project
  publication-title: Nat Genet
  doi: 10.1038/ng.2764
– volume: 11
  start-page: 77
  year: 2005
  ident: 44
  article-title: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
  publication-title: Nat Med
  doi: 10.1038/nm1161
– volume: 10
  start-page: 776
  year: 2009
  ident: 45
  article-title: Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes
  publication-title: EMBO Rep
  doi: 10.1038/embor.2009.88
– volume: 23
  start-page: 99
  year: 2015
  ident: 38
  article-title: Targeting Histone Deacetylases in Diseases: Where Are We?
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2013.5776
– volume: 6
  start-page: 227
  year: 2005
  ident: 27
  article-title: The SET-domain protein superfamily: protein lysine methyltransferases
  publication-title: Genome Biol
  doi: 10.1186/gb-2005-6-8-227
– volume: 13
  start-page: 343
  year: 2012
  ident: 5
  article-title: Histone methylation: a dynamic mark in health, disease and inheritance
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg3173
– volume: 46
  start-page: 465
  year: 2015
  ident: 11
  article-title: Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review)
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2014.2766
– year: 2017
  ident: 39
  article-title: miR-194-5p/BCLAF1 deregulation in AML tumorigenesis
  publication-title: Leukemia
  doi: 10.1038/leu.2017.64
– volume: 14
  start-page: 2249
  year: 2015
  ident: 50
  article-title: Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-15-0429
– volume: 416
  start-page: 552
  year: 2002
  ident: 51
  article-title: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
  publication-title: Nature
  doi: 10.1038/416552a
– volume: 74
  start-page: 652
  year: 2014
  ident: 10
  article-title: Role of CHD5 in human cancers: 10 years later
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-3056
– volume: 19
  start-page: 1187
  year: 2015
  ident: 19
  article-title: Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia
  publication-title: Expert Opin Ther Targets
  doi: 10.1517/14728222.2015.1051728
– volume: 30
  start-page: 806
  year: 2016
  ident: 18
  article-title: Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.09.014
– volume: 94
  start-page: 2308
  year: 2012
  ident: 31
  article-title: Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2012.06.003
– volume: 8
  start-page: 57
  year: 2016
  ident: 29
  article-title: Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
  publication-title: Clin Epigenetics
  doi: 10.1186/s13148-016-0223-4
– volume: 8
  start-page: e83737
  year: 2013
  ident: 24
  article-title: Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0083737
– volume: 6
  start-page: 886
  year: 2015
  ident: 48
  article-title: HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2816
– year: 2016
  ident: 21
  article-title: c-Myc modulation & acetylation is a key HDAC inhibitor target in cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2388
– volume: 22
  start-page: 2368
  year: 2013
  ident: 33
  article-title: MePR: a novel human mesenchymal progenitor model with characteristics of pluripotency
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2012.0498
– volume: 69
  start-page: 121
  year: 2015
  ident: 30
  article-title: Epigenetic-based therapy: From single- to multi-target approaches
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2015.10.016
– year: 2015
  ident: 34
  article-title: Secretome profiling of cytokines and growth factors reveals that neuro-glial differentiation is associated with the down-regulation of Chemokine Ligand 2 (MCP-1/CCL2) in amniotic fluid derived-mesenchymal progenitor cells
  publication-title: Proteomics
  doi: 10.1002/pmic.201500223
– start-page: 0
  year: 2016
  ident: 28
  article-title: Identification and characterization of PKF118-310 as a KDM4A inhibitor
  publication-title: Epigenetics
  doi: 10.1080/15592294.2016.1249089
– volume: 8
  start-page: e84147
  year: 2013
  ident: 26
  article-title: Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0084147
– volume: 153
  start-page: 38
  year: 2013
  ident: 15
  article-title: Interplay between the cancer genome and epigenome
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.008
– volume: 3
  start-page: e366
  year: 2012
  ident: 43
  article-title: Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2012.109
– volume: 5
  start-page: 108
  year: 2015
  ident: 3
  article-title: The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis
  publication-title: Front Oncol
  doi: 10.3389/fonc.2015.00108
– volume: 13
  start-page: e29
  year: 2011
  ident: 8
  article-title: Bromodomains as therapeutic targets
  publication-title: Expert Rev Mol Med
  doi: 10.1017/S1462399411001992
– reference: 25405367 - Int J Oncol. 2015 Feb;46(2):465-73
– reference: 22109698 - J Cell Biochem. 2012 Apr;113(4):1292-301
– reference: 24367611 - PLoS One. 2013 Dec 19;8(12 ):e83737
– reference: 23103179 - Mol Oncol. 2012 Dec;6(6):657-82
– reference: 20388510 - FEBS Lett. 2010 Jun 18;584(12):2662-9
– reference: 27276561 - N Engl J Med. 2016 Jun 9;374(23 ):2209-2221
– reference: 19498465 - EMBO Rep. 2009 Jul;10(7):776-82
– reference: 27767379 - Epigenetics. 2017 Mar 4;12 (3):198-205
– reference: 24419087 - Cancer Res. 2014 Feb 1;74(3):652-8
– reference: 17694081 - Oncogene. 2007 Aug 13;26(37):5395-407
– reference: 22923494 - Blood. 2012 Oct 11;120(15):3058-68
– reference: 20871596 - Nature. 2010 Dec 23;468(7327):1067-73
– reference: 26362997 - Clin Cancer Res. 2015 Nov 1;21(21):4767-73
– reference: 27222667 - Clin Epigenetics. 2016 May 24;8:57
– reference: 19474426 - N Engl J Med. 2009 May 28;360(22):2289-301
– reference: 27846393 - Cancer Cell. 2016 Nov 14;30(5):806-821
– reference: 22473383 - Nat Rev Genet. 2012 Apr 03;13(5):343-57
– reference: 26257180 - Cell Rep. 2015 Aug 18;12(7):1184-95
– reference: 15619633 - Nat Med. 2005 Jan;11(1):77-84
– reference: 27851970 - Cell Rep. 2016 Nov 15;17 (8):2087-2100
– reference: 22709867 - Biochimie. 2012 Nov;94(11):2308-13
– reference: 21941284 - Nat Rev Cancer. 2011 Sep 23;11(10):726-34
– reference: 24367637 - PLoS One. 2013 Dec 19;8(12 ):e84147
– reference: 26075180 - Front Oncol. 2015 May 26;5:108
– reference: 26206331 - Mol Cancer Ther. 2015 Oct;14 (10 ):2249-59
– reference: 21933453 - Expert Rev Mol Med. 2011 Sep 13;13:e29
– reference: 23540689 - Cell. 2013 Mar 28;153(1):38-55
– reference: 27358484 - Clin Cancer Res. 2017 May 15;23 (10 ):2542-2555
– reference: 20920340 - BMC Cancer. 2010 Oct 04;10:524
– reference: 21723201 - Cancer Cell. 2011 Jul 12;20(1):25-38
– reference: 26028314 - Expert Opin Ther Targets. 2015;19(9):1187-202
– reference: 24382114 - Antioxid Redox Signal. 2015 Jul 1;23(1):99-126
– reference: 26689352 - J Med Chem. 2016 Feb 25;59(4):1471-91
– reference: 21941618 - Genes Cancer. 2011 Jun;2(6):618-30
– reference: 24566867 - Cancer Res. 2014 Apr 15;74(8):2328-39
– reference: 20048137 - Mol Interv. 2009 Dec;9(6):314-23
– reference: 22904103 - Clin Cancer Res. 2012 Oct 15;18(20):5526-34
– reference: 21979880 - Leukemia. 2012 Apr;26(4):662-74
– reference: 8839862 - Blood. 1996 Oct 1;88(7):2671-82
– reference: 11932749 - Nature. 2002 Apr 4;416(6880):552-6
– reference: 16086857 - Genome Biol. 2005;6(8):227
– reference: 24325601 - J Med Chem. 2014 Jan 9;57(1):42-55
– reference: 22789535 - Cancer Cell. 2012 Jul 10;22(1):9-20
– reference: 25131830 - Nat Rev Drug Discov. 2014 Sep;13(9):673-91
– reference: 28216661 - Leukemia. 2017 Nov;31(11):2315-2325
– reference: 20970499 - Biochim Biophys Acta. 2011 Aug;1812(8):818-23
– reference: 26494003 - Int J Biochem Cell Biol. 2015 Dec;69:121-31
– reference: 22875003 - Cell Death Dis. 2012 Aug 09;3:e366
– reference: 25473896 - Oncotarget. 2015 Jan 20;6(2):886-901
– reference: 23597129 - Stem Cells Dev. 2013 Sep 1;22(17 ):2368-83
– reference: 26604074 - Proteomics. 2016 Feb;16(4):674-88
– reference: 24071849 - Nat Genet. 2013 Oct;45(10):1113-20
– reference: 18755984 - Blood. 2008 Nov 15;112(10):4220-6
– reference: 23634996 - N Engl J Med. 2013 May 30;368(22):2059-74
SSID ssj0000547829
Score 2.218794
Snippet Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid...
SourceID pubmedcentral
hal
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 25630
SubjectTerms Cancer
Life Sciences
Research Paper
Title Combined HAT/EZH2 modulation leads to cancer-selective cell death
URI https://www.ncbi.nlm.nih.gov/pubmed/29876013
https://www.proquest.com/docview/2051662357
https://hal.science/hal-01873834
https://pubmed.ncbi.nlm.nih.gov/PMC5986654
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB613QsXBGKB8KjMihNS-rBjJzkgVKGWaLXLqZUqLpHjhxapm0AfCP49M0napVD2mowTacZjf188-QbgbYyITfvIhF5bGZKgXJgWSoTeu1hrLo0a0d_I159Vtogul3LZgX17q9aBm5PUjvpJLdarwc_vvz5gwr-nhE-U4MOKdAzqwukB8h2edOGsPi6iSr4W7TdS3xHuh2l7tnlyJGkDIwtHliKONqruDZVJ_otB_y6l_GNvmj2Chy2oZJNmFjyGjiufwARTHWmvsyybzIfTLxlnt5Vtu3WxFcZ2w7YVMxT2dbip--Hg0sfoUz6zhAzPYTGbzj9mYdswITQCEzH0yjornI0LjixCylhbLexIWa2FdAjNkpF3VmpPxWmpiYuxKHQqvCgKbTj34in0yqp0z4GZxEUGrVMe88hajdYiQuzjtHeJkUkAo713ctOqiVNTi1VOrIJ8m9_5Nq99G8C7w5BvjZTGfcYX6PKDHYlgZ5OrnK5RG0Hk1dGPcQBv9hHJMSvIP7p01W6Tc1xrlCIpnwCeNRE6PGsf4ADio9gdvez4Tvn1plbeJjF7JaMX_33mS3iAiCqh8gLOX0Fvu96514hatkUfup-W4349I38DS33vVQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combined+HAT%2FEZH2+modulation+leads+to+cancer-selective+cell+death&rft.jtitle=Oncotarget&rft.au=Petraglia%2C+Francesca&rft.au=Singh%2C+Abhishek+A&rft.au=Carafa%2C+Vincenzo&rft.au=Nebbioso%2C+Angela&rft.date=2018-05-22&rft.eissn=1949-2553&rft.volume=9&rft.issue=39&rft.spage=25630&rft_id=info:doi/10.18632%2Foncotarget.25428&rft_id=info%3Apmid%2F29876013&rft.externalDocID=29876013
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon